Real-World Study Finds Injectable Obesity Medications Yield Less Weight Loss Than Expected
A Cleveland Clinic study shows that in real-world settings, injectable obesity medications like semaglutide and tirzepatide often produce smaller weight loss due to treatment discontinuation and lower dosages used outside clinical trials.
Recent research from Cleveland Clinic reveals that injectable GLP-1 medications such as semaglutide and tirzepatide, approved for obesity management, tend to produce less weight loss in everyday clinical settings compared to controlled clinical trials. The study highlights that many patients discontinue treatment prematurely or use lower maintenance dosages, which adversely impacts outcomes, including blood sugar control in prediabetic individuals.
The study, published in the Obesity Journal, involved 7,881 adult patients with severe obesity and included a subset with pre-diabetes. Participants started treatment with semaglutide or tirzepatide between 2021 and 2023, but more than 20% discontinued early, and 32% discontinued later, often at lower dosages. On average, patients who ceased treatment early lost only about 3.6% of their body weight after a year, while those who continued late or persisted with higher doses achieved greater weight reductions, with the latter group losing approximately 11.9% to 18% of their body weight.
The study also found that patients who maintained treatment on higher doses experienced more significant weight loss and better blood sugar regulation. Factors linked to achieving a 10% or greater weight loss included continuous medication use, higher doses, female gender, and the use of tirzepatide over semaglutide.
Treatment discontinuation was primarily due to medication costs, insurance issues, side effects, and shortages. Despite weight loss differences, patients who stopped medication maintained relatively stable weight trajectories. The findings suggest that supporting patients in continued treatment and optimizing dosage could lead to better health outcomes.
This research underscores the importance of adherence and dosage in the real-world effectiveness of obesity medications, emphasizing the need for strategies to improve patient retention and compliance for optimal results.
Source: https://medicalxpress.com/news/2025-06-medications-obesity-smaller-weight-loss.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Groundbreaking Pilot Study Highlights Role of Music Therapy in Managing Postoperative Pain After Pancreatic Surgery
A new pilot study reveals that music therapy can effectively reduce pain and improve recovery after pancreatic surgery, paving the way for enhanced holistic pain management strategies.
Higher Psychotropic Medication Use in Elderly Residents with Dementia
Research indicates that residents with dementia in aged care are prescribed antipsychotic medications at twice the rate of those without dementia, highlighting ongoing challenges in safe medication management for older adults.
Public Trust in AI-Generated Health Information Rises in the U.S.
A 2025 survey shows that nearly two-thirds of Americans trust AI-generated health information, highlighting its growing role in online health searches despite concerns about accuracy and reliance on medical professionals.
Living in Underserved Neighborhoods May Elevate Inflammation and Dementia Biomarkers
Research shows that residing in socioeconomically disadvantaged neighborhoods may raise inflammation levels and dementia-related biomarkers, potentially increasing Alzheimer's disease risk.